124 related articles for article (PubMed ID: 8723496)
1. Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.
Wood PJ; Ioannides-Demos LL; Bastone EB; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1996 May; 40(5):1321-4. PubMed ID: 8723496
[TBL] [Abstract][Full Text] [Related]
2. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
Ioannides-Demos LL; Liolios L; Wood P; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
4. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
Zhu ZY; Li RC
J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
Li RC; Zhu ZY; Lee SW; Raymond K; Ling JM; Cheng AF
Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
[TBL] [Abstract][Full Text] [Related]
6. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
7. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
[TBL] [Abstract][Full Text] [Related]
8. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
9. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.
den Hollander JG; Mouton JW; van Goor MP; Vleggaar FP; Verbrugh HA
Antimicrob Agents Chemother; 1996 Mar; 40(3):784-6. PubMed ID: 8851612
[TBL] [Abstract][Full Text] [Related]
10. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.
den Hollander JG; Fuursted K; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1998 Apr; 42(4):749-54. PubMed ID: 9559777
[TBL] [Abstract][Full Text] [Related]
11. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.
Bastone EB; Li SC; Ioannides-Demos LL; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1993 Apr; 37(4):914-7. PubMed ID: 8494392
[TBL] [Abstract][Full Text] [Related]
12. Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing
Müsken M; Pawar V; Schwebs T; Bähre H; Felgner S; Weiss S; Häussler S
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297365
[TBL] [Abstract][Full Text] [Related]
13. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P
Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model.
Cao B; Christophersen L; Thomsen K; Sønderholm M; Bjarnsholt T; Jensen PØ; Høiby N; Moser C
J Antimicrob Chemother; 2015 Jul; 70(7):2057-63. PubMed ID: 25786481
[TBL] [Abstract][Full Text] [Related]
15. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
den Hollander JG; Mouton JW; Verbrugh HA
Antimicrob Agents Chemother; 1998 Apr; 42(4):744-8. PubMed ID: 9559776
[TBL] [Abstract][Full Text] [Related]
16. The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics.
Li RC; Zhu ZY
J Chemother; 2002 Dec; 14(6):579-83. PubMed ID: 12583549
[TBL] [Abstract][Full Text] [Related]
17. Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.
Rees VE; Bulitta JB; Oliver A; Tsuji BT; Rayner CR; Nation RL; Landersdorfer CB
J Antimicrob Chemother; 2016 Nov; 71(11):3157-3167. PubMed ID: 27521357
[TBL] [Abstract][Full Text] [Related]
18. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
[TBL] [Abstract][Full Text] [Related]
19. Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.
Loose M; Naber KG; Shields P; Reinhart H; Wagenlehner FME
Int J Antimicrob Agents; 2018 Mar; 51(3):422-426. PubMed ID: 29158143
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
Canis F; Cavallo JD; Husson MO
Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
